GlobeNewswire

ImageneBio Reports Third Quarter 2026 Financial Results
09/11/2026
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended September 30, 2026, and provided a company update. Company [...]
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
09/11/2026
Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA on the non-IPF ILD-related chronic cough [...]
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
09/11/2026
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A EVERLAST-A responses continued to deepen to 71% PASI 100 at Week 28, 6 months after last [...]
Globus Medical to Participate in Jefferies Global Healthcare Conference
09/11/2026
AUDUBON, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Jefferies Global Healthcare [...]
Harrow Announces Third Quarter 2026 Financial Results
09/11/2026
Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and approximately 84% of [...]
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026
09/11/2026
Awarded $15 Million Procurement Contract from Canadian Department of National Defence for Oral TPOXX in October Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SIGA [...]
Xenon Reports Q3 2026 Financial Results and Provides Business Update
09/11/2026
New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies [...]
POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN
09/11/2026
TEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
09/11/2026
Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track [...]
SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.
09/11/2026
Concludes 30-Year Tenure Leading Development of TPOXX®, the First FDA-Approved Antiviral for the Treatment of Smallpox NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies (NASDAQ: SIGA), a commercial stage [...]
IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
09/11/2026
NEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious [...]
SodaPeak Launch 2026 Advanced Soda Peak Gummies for Male Vitality and Energy Supplement New Information For Multi-Ingredient And Benefits.
09/11/2026
SodaPeak introduces Soda Peak Gummies in the USA, a multi-ingredient dietary supplement formulated for male vitality and energy wellness, with details on ingredients, product features and usage information. New York, [...]
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
09/11/2026
Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable [...]
Solana Company to Release Third Quarter 2026 Operating Results on November 11, 2026
09/11/2026
PHILADELPHIA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to [...]
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
09/11/2026
Press release – No. 23 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, November 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology [...]
Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
09/11/2026
Publication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first approved CAR T-cell [...]
Hinge Bio Shares Encouraging Clinical Data for HB2198, a Novel B-Cell Depleting Agent for Treating Autoimmune Disease, at ACR Convergence 2026
09/11/2026
Encouraging safety and pharmacodynamic activity observed with HB2198 in normal healthy volunteers was presented with additional preclinical data at the American College of Rheumatology (ACR) Convergence 2026 REDWOOD [...]
NTG Nordic Transport Group publishes interim report for Q3 2026
09/11/2026
Company announcement no. 47 – 26 09 November 2026 NTG Nordic Transport Group publishes interim report for Q3 2026 The interim report for Q3 2026 is enclosed. In connection with publication of the results for Q3 2026, a [...]
NTG Nordic Transport Group A/S – Launch of medium-term financial targets for 2029-2031
09/11/2026
Company announcement no. 46 – 26 09 November 2026 NTG Nordic Transport Group A/S – Launch of medium-term financial targets for 2029-2031 NTG Nordic Transport Group A/S (“NTG”) today launches medium-term financial [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum